Featured Articles

1. CTIS Results In The Spotlight 9/15/2026

   A new study finds fewer than half of EU Clinical Trial Information System (CTIS) trials met results reporting requirements. The EMA is now watching more closely. Here’s what sponsors need to know.

2. Digital Twins: From Protocol Design to Predictive Study Execution 9/14/2026

   A growing generation of AI-enabled digital twin approaches offers a new path. Instead of treating the protocol as a static document, organizations can model it as a dynamic system.

3. Obesity Clinical Trials: A Promising Research Landscape 9/14/2026

   Obesity is a hot topic in the pharmaceutical industry, with GLP-1 drugs dominating the headlines. Globally, there are 5,189 obesity trials, of which 1,119 are planned or ongoing.

4. The State Of The Clinical Development Race 8/14/2026

   Every medicine reaching a patient has run a race from a crowded grid of candidates through the clinical development circuit to the market launch podium. Catch up on what’s in store for this season.

5. Examining The New Look For Biotech 8/14/2026

   According to a recent episode of Citeline’s podcast series, “Small Biotechs, Big Decisions,” biotech is developing a new look that is leaner and savvier when it comes to working with partners.

6. How AI Is Revolutionizing Clinical Development 8/14/2026

   Artificial intelligence is expanding from the preclinical phase of clinical trials into Phases I–III, where is it being used in protocol design, site selection, feasibility, and patient recruitment.

7. Under Half Of CTIS Trials Met Results Reporting Requirements 8/14/2026

   A first assessment of compliance on EU Clinical Trial Information System (CTIS) found fewer than half of European Phase II–IV drug trials legally required to post results fully complied on time.

8. Subject Matter Experts Matter In Decision-Making 7/21/2026

   Expert-led ontology and taxonomy practices help organize data into meaningful hierarchies, making it easier to connect diseases, drug targets, and strategic insights that support stronger decisions.

9. Busy Quarter For Gene, Cell, RNA Therapies 7/21/2026

   Explore how Q2 brought renewed momentum for gene, cell, and RNA therapies and grew confidence in the future of advanced medicine with rising approvals, expanding pipelines, and increased investment.

10. Rapid Expansion Of Peptide And Nanobody Drug Conjugates 7/21/2026

    Peptide and nanobody drug conjugates are gaining momentum, with 106 active programs identified globally. Learn more about the fast-evolving space for targeted drug delivery and competitive opportunities.